gn exchange, as compared with the 2008 second quarter. The 2% increase, excluding the impact of foreign exchange, was primarily due to higher sales of Wyeth's key pharmaceutical franchises PREVNAR
((R)) (outside the U.S. and Canada) and Nutritional products, along with higher sales of PRISTIQ
((R)) and the Hemophilia family and higher Enbrel alliance revenue. These increases were partially offset by decreased sales of EFFEXOR((R))
due primarily to increased generic competition in international markets. Excluding the impact of foreign exchange, net revenue for the 2009 second quarter for the Pharmaceuticals, Consumer Healthcare and Animal Health segments increased 3%, 2% and 1%, respectively.
Gross margin, excluding certain significant items, as a percentage of net revenue, increased 0.7 percentage points to 73.2% for the 2009 second quarter from 72.5% for the 2008 second quarter.
Selling, general and administrative expenses, excluding certain significant items, decreased 9% for the 2009 second quarter versus the 2008 second quarter and decreased 4%, excluding the impact of foreign exchange. This decrease, excluding the impact of foreign exchange, was primarily due to cost savings related to the Company's productivity initiatives, which were partially offset by increased pension expense.
Research and development expenses, excluding certain significant items, increased 7% for the 2009 second quarter versus the 2008 second quarter and increased 8%, excluding the impact of foreign exchange. The increase was primarily due to increased clinical trial spending, including oncology projects and Prevnar 13 adult, as well as costs related to a recently announced in-licensing transaction.
Interest expense, net was $83.0 million for the 2009 second quarter as compared with $18.7 million for the 200Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine news :1
. Wyeth Announces Results of the Companys Offer Relating to Holder Right to Surrender Convertible Debentures2
. Wyeth Consumer Healthcare Announces the Availability of New Centrum Ultra Line of Multivitamins Specially Formulated For Women and Men3
. Wyeths Prevenar 13* Receives First Approval4
. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products5
. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders6
. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market7
. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project8
. DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 9
. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care10
. U.S. and 16 States Join Suits Against Pharmaceutical Giant, Wyeth11
. Wyeth Reports Earnings Results for the 2009 First Quarter